Network for Translational Research: Optical Imaging

The summary for the Network for Translational Research: Optical Imaging grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Network for Translational Research: Optical Imaging: The National Cancer Institute (NCI) invites applications for cooperative agreement (U54) awards to establish a Specialized Research Resource Center that will participate as a member of a network of inter-disciplinary, inter- institutional research teams for the purpose of supporting translational research in optical imaging and/or spectroscopy in vivo. The network is to be named the "Network for Translational Research: Optical Imaging" (NTROI) and will operate under the guidance of a Steering Committee (SC). The goal of this Request for Applications (RFA) is to organize a consortium with flexibility in scope, funding, and incentives to encourage inter- and intra- team collaborations on translational cancer research. The objective is to accelerate the pace of translational research by developing a consensus process to improve methods for system integration, optimization and validation of next-generation in vivo optical imaging and/or spectroscopy methods and technologies, including contrast agents. Investigators are encouraged to include in vivo molecular imaging methods that give information about molecular events in cells or the extra-cellular milieu. The research scope includes feasibility studies for the detection of pre-cancerous lesions, cancer detection and diagnosis, and measurement or prediction of response to therapy. Applications are solicited from preformed consortia, to be referred to as Teams. Approximately three such teams will be selected from applications that receive high priority scores and are most responsive to the goals of this RFA. Each team must include investigators from at least two different institutions, and the team may include investigators from academia, national laboratories, industry or intramural laboratories of the National Institutes of Health. (NIH investigators may participate in applications as investigators or collaborators, but not as principal investigators. They may not request or receive funds from this program.) Broad, multi-disciplinary teams are expected to include a variety of expertise, such as molecular biologists, chemists, physicists, optical and computer engineers, imaging scientists and physicians. Involvement of basic and clinical scientists who may not have a specific research record in cancer research, but who have the potential to provide experience crucial for the success of this network are considered important. Partnerships with industry and small business are encouraged for each team to enhance technology dissemination.